FKBP8 recruits LC3A to mediate Parkin-independent mitophagy
At Perfect B in Doral, we address this through a subcutaneous injection protocol of 5 injections per week for up to 6 weeks, which allows NAD+ to accumulate gradually at the cellular level without the chest tightness and flushing that standard IV infusions often produce
Scientists have found that as we age, NAD levels decline (2)
Likewise, tirzepatide (Mounjaro), a dual GIP/GLP-1 agonist, has outperformed many comparators in clinical trials, offering additional benefits like improved lipid profiles
The trial is set to conclude in the first quarter of 2027
Methods and results: First, 16 candidate genes were obtained by intersecting WGCNA, differential expression analysis results, and targets related to ferroptosis and gut microbiota